A Phase II Study of Tri-weekly XELIRI with Bevacizumab for patient with unresectable or recurrent Colorectal Cancer as first -line chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 03 May 2017
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 25 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 01 Aug 2011 New trial record